BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Sells 6,019 Shares of Hologic, Inc. (NASDAQ:HOLX)

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp cut its holdings in Hologic, Inc. (NASDAQ:HOLX) by 13.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 38,944 shares of the medical equipment provider’s stock after selling 6,019 shares during the quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in Hologic were worth $3,172,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. Innealta Capital LLC purchased a new stake in Hologic in the second quarter worth about $25,000. Wolff Wiese Magana LLC purchased a new stake in shares of Hologic in the 3rd quarter worth approximately $25,000. Sunbelt Securities Inc. bought a new position in Hologic during the 2nd quarter valued at approximately $37,000. First Horizon Advisors Inc. raised its stake in Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock valued at $39,000 after buying an additional 134 shares during the last quarter. Finally, Cromwell Holdings LLC boosted its holdings in Hologic by 330.2% in the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock worth $44,000 after acquiring an additional 416 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on HOLX shares. UBS Group lifted their price target on Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. StockNews.com upgraded shares of Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. JPMorgan Chase & Co. raised their price target on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research report on Tuesday, November 5th. Mizuho lowered their price objective on Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th. Finally, Evercore ISI lifted their target price on Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a report on Tuesday, October 1st. Four equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $89.91.

Hologic Stock Down 1.9 %

HOLX stock opened at $77.47 on Wednesday. The company has a market cap of $17.58 billion, a price-to-earnings ratio of 23.26, a P/E/G ratio of 2.49 and a beta of 0.96. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. The business’s 50-day moving average is $80.13 and its two-hundred day moving average is $78.52. Hologic, Inc. has a fifty-two week low of $67.59 and a fifty-two week high of $84.67.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The company had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. During the same quarter last year, the firm posted $0.89 earnings per share. The firm’s revenue was up 4.5% compared to the same quarter last year. As a group, analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.